Literature DB >> 2360257

Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers.

P Fontaine1, C Perreault.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2360257     DOI： 10.1097/00007890-199006000-00032

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  7 in total

1.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Authors:  K R Cooke; A Gerbitz; J M Crawford; T Teshima; G R Hill; A Tesolin; D P Rossignol; J L Ferrara
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

3.  Evaluation of in vitro cytotoxic T lymphocyte assays as a predictive test for the occurrence of graft vs host disease.

Authors:  P Fontaine; J Langlais; C Perreault
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

4.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Authors:  K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

5.  Differences in MHC-class I presented minor histocompatibility antigens extracted from normal and graft-versus-host disease (GVHD) mice.

Authors:  M Bruley Rosset; V Tieng; D Charron; A Toubert
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

6.  A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies.

Authors:  Chase D McCann; Christiaan H van Dorp; Ali Danesh; Adam R Ward; Thomas R Dilling; Talia M Mota; Elizabeth Zale; Eva M Stevenson; Shabnum Patel; Chanson J Brumme; Winnie Dong; Douglas S Jones; Thomas L Andresen; Bruce D Walker; Zabrina L Brumme; Catherine M Bollard; Alan S Perelson; Darrell J Irvine; R Brad Jones
Journal:  J Exp Med       Date:  2021-05-14       Impact factor: 14.307

7.  Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.

Authors:  Yang Jo Chung; Terry J Fry; Peter D Aplan
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.